In summary, our results indicate that syngeneic IL-15/IL-12-conditioned NK cell therapy promotes tumor-specific T cell responses, at least in part, through activation of cDC1s and cDC2s in metastatic lung. This evidence concerns the gene IL15 and neoplasm.